Please sign in to follow a disease.
Could a One-Time injection of your own immune cells protect your kidneys?
NCT ID NCT06866158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether a single injection of a person's own immune cells (dendritic cells and lymphocytes) can reduce kidney damage in type 2 diabetes. The cells are processed in a lab and then given back under the skin. Researchers will measure urine protein levels and kidney function over four weeks in 80 adults. The goal is to see if this approach can calm inflammation and protect the kidneys.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- autologous dendritic cells and lymphocytes matured with SARS-CoV-2 S protein
- What this could lead to
- If it works, this could point toward a new way to slow or reverse kidney damage in people with type 2 diabetes, potentially reducing the need for dialysis or transplant.
- What could go wrong
- This is a very early (Phase 1/2), small, single-arm trial with no placebo group, so results may be due to chance or natural variation. The treatment uses a coronavirus protein to mature the cells, which is unusual and its safety and effectiveness are unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
80 people
The number who actually took part.
- Started
-
May 2024
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female over 18 years old 2. Understands and agrees to comply with study procedures by providing written informed consent. 3. In the investigator's judgment, the subject is able and willing to comply with study procedures. 4. In the investigator's judgment, the subject is in generally good physical and mental health. This includes the following factors: * Age \> 65 years * Mild to moderate obesity (BMI 30 to 40) * Controlled hypertension with medication * Controlled hyperlipidemia with medication * Mild chronic lung disease * Previously diagnosed with cancer and in remission for at least 1 year 5. Meets the diagnostic criteria for Type 2 Diabetes Mellitus (DM) according to Indonesia's Endocrinology Society (PERKENI) 2021. 6. eGFR ≥ 30 mL/min/1.73 m². 7. Urinary albumin-creatinine ratio (UACR) ≥ 30 mg/g. Exclusion Criteria: 1. Receiving immunosuppressive treatments such as corticosteroids, hydroxychloroquine, methotrexate, cyclophosphamide, and others within the last 4 weeks. 2. Known to have other kidney diseases (e.g., polycystic kidney disease, lupus nephritis, ANCA-associated vasculitis, etc.). 3. Known to have other conditions that can cause albuminuria (e.g., myeloma, rhabdomyolysis, paroxysmal nocturnal hemoglobinuria, orthostatic albuminuria, etc.). 4. Diagnosed with other types of diabetes (Type 1 DM, gestational DM, or other forms of DM). 5. Positive pregnancy test. 6. Known to have immunodeficiency diseases such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV); no blood testing required. 7. Requires oxygen supplementation. 8. Diagnosed with invasive cancer and currently receiving anti-cancer therapy, except for hormonal therapy for breast or prostate cancer. 9. History of thromboembolism or a genetic predisposition to thromboembolism, or currently on anti-thromboembolic therapy other than low-dose aspirin. 10. Physical or mental disabilities preventing normal daily activities. 11. In the investigator's judgment, any illness or medical condition that may hinder the subject's participation, including acute, subacute, intermittent, or chronic diseases that could place the subject at risk of injury, prevent compliance with the study protocol, or interfere with study assessments. 12. Measurable parameters include: * Severe obesity: BMI \> 40 * Uncontrolled hypertension: systolic \>180 mmHg, diastolic \>100 mmHg 13. Unwilling to sign the written informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic kidney disease (DKD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gatot Soebroto Central Army Hospital
Jakarta Pusat, DKI Jakarta - Jakarta, 10410, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seaweed compounds put to the test against diabetic kidney damage
- Can a strong support network help people with diabetic kidney disease take better care of themselves?
- New strategy aims to protect kidneys and hearts in diabetes patients
- New registry aims to uncover real-world diabetic kidney disease care in underserved groups
- New drug aims to shield kidneys and heart in diabetic patients
- New drug combo aims to protect kidneys in diabetes